Skip to content

Twitter Linkedin Instagram

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: October 14, 2019

Epichem New CEO and Board Additions

News & Announcements 2019By Richard Mollard October 14, 2019

191014_Epichem New CEO and Board Additions

Recent Articles

Appendix 3B – Exercise of Options
November 8, 2019
Progress in Recruitment for Phase II Trial in Dogs
November 4, 2019
Appendix 4C and Quarterly Update
November 1, 2019
31 October, Top 20 Shareholders
November 1, 2019

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

Nic Brownbill @NicBrownbill1·

Phase II anti-cancer trial results expected by year end. $PAA looking to validate the previous canine lymphoma trial results that showed MPL in liquid form was safe and significantly induced progression free survival.@PharmAust https://t.co/bVUyczOGl8

Reply on Twitter 1194147471514976256 Retweet on Twitter 11941474715149762562 Like on Twitter 119414747151497625618 Twitter 1194147471514976256

Copyright © 2019 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions